The National Institute for Health and Care Excellence has recommended Pfizer's Elrexfio for patients with relapsed and refractory multiple myeloma under managed access by the Cancer Drugs Fund. The decision, supported by MagnetisMM-3 study results, allows patients who have undergone at least three lines of treatment to access the drug.